首页|期刊导航|上海针灸杂志|针刺联合穴位贴敷治疗非创伤性股骨头坏死的疗效观察及对骨代谢、炎症因子水平的影响

针刺联合穴位贴敷治疗非创伤性股骨头坏死的疗效观察及对骨代谢、炎症因子水平的影响OA

Therapeutic efficacy observation of acupuncture combined with acupoint application in treating non-traumatic osteonecrosis of the femoral head and the impact on bone metabolism and inflammatory factor levels

中文摘要英文摘要

目的 观察针刺联合穴位贴敷治疗非创伤性股骨头坏死的临床疗效,并分析其对骨代谢、骨髓水肿以及炎症因子水平的影响.方法 选取 100 例股骨头坏死患者随机分为对照组和观察组,每组 50 例.对照组接受常规中成药联合穴位贴敷治疗,观察组在对照组基础上联合针刺治疗.比较两组治疗前后的疼痛视觉模拟量表(visual analog scale,VAS)评分、Harris 评分、骨代谢指标[血清骨钙素(bone-γ-carboxyglutamic acid-containing protein,BGP)、Ⅰ型胶原羧基端肽β特殊序列(β isomer of C-terminal telopeptide of typeⅠ collagen,β-CTX)和Ⅰ型前胶原氨基端前肽(procollagen type Ⅰ N-terminal propeptide,PINP)]、血清炎症因子[白细胞介素-6(interleukin-6,IL-6)和肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)]水平及磁共振成像(magnetic resonance imaging,MRI)骨髓水肿改善情况,以及两组临床疗效和不良反应发生情况.结果 观察组总有效率达93.6%,显著高于对照组的81.6%(P<0.05).治疗后,两组VAS评分均较治疗前下降(P<0.05),且观察组低于对照组(P<0.05).治疗后,两组Harris评分均较治疗前升高(P<0.05),且观察组高于对照组(P<0.05).MRI 显示两组骨髓水肿等级分布优于治疗前(P<0.05),且观察组优于对照组(P<0.05).治疗后,两组血清骨代谢指标(BGP 升高,β-CTX 降低)均改善(P<0.05),炎性因子指标均下降(P<0.05),观察组均显著优于对照组(P<0.05).两组均未发生严重不良反应.结论 在常规中成药治疗基础上,针刺联合穴位贴敷治疗非创伤性股骨头坏死可改善临床症状,减轻患者疼痛反应,并抑制炎症反应,使炎症因子水平更低,加用针刺可增强穴位贴敷与口服药物的疗效,疗效优于单纯穴位贴敷加口服药物,且具有较好的安全性.

Objective To observe the clinical efficacy of acupuncture combined with acupoint application in treating non-traumatic osteonecrosis of the femoral head(NONFH)and analyze the impact on bone metabolism,bone marrow edema,and inflammatory factor levels.Method One hundred patients with NONFH were recruited and randomized into a control or observation group,with 50 cases in each group.The control group was treated with conventional Chinese patent drugs plus acupoint application,and the observation group received acupuncture treatment in addition to the intervention in the control group.The two groups were compared in terms of the post-treatment improvement in the pain visual analog scale(VAS)score,Harris score,bone metabolism indicators[serum bone-γ-carboxyglutamic acid-containing protein(BGP),serum β isomer of C-terminal telopeptide of type I collagen(β-CTX),and serum procollagen type Ⅰ N-terminal propeptide(PINP)],serum inflammatory factor levels[interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)],and bone marrow edema on magnetic resonance imaging(MRI).The clinical efficacy and adverse reactions were also compared.Result The observation group achieved a total effective rate of 93.6%,significantly higher than 81.6%in the control group(P<0.05).After treatment,the VAS score decreased in both groups(P<0.05)and was lower in the observation group than in the control group(P<0.05).After treatment,both groups showed an increase in the Harris score(P<0.05),and the observation group was higher than the control group(P<0.05).MRI demonstrated post-treatment improvement in bone marrow edema grading in both groups(P<0.05),and the observation group was superior to the control group(P<0.05).After treatment,both groups showed improvement in serum bone metabolism indicators(elevated BGP and declined β-CTX)(P<0.05),along with decreased inflammatory factor levels(P<0.05);the observation group surpassed the control group in these measures(P<0.05).Neither group experienced significant adverse reactions.Conclusion Based on conventional Chinese patent drugs,acupuncture plus acupoint application can improve clinical symptoms in NONFH,reducing pain,inhibiting inflammatory reactions,and further decreasing inflammatory factor levels.The additional use of acupuncture can strengthen the efficacy of acupoint application and oral medication,producing more significant efficacy,with a good safety profile.

刘哲;阎晓霞;张宇;李骏巍;张胜杰

河南中医药大学,郑州 450046河南省洛阳正骨医院(河南省骨科医院),郑州 450016河南中医药大学,郑州 450046河南中医药大学,郑州 450046河南中医药大学,郑州 450046

医药卫生

针刺疗法穴位贴敷法针药并用股骨头坏死骨代谢骨髓水肿炎症因子

Acupuncture therapyAcupoint applicationAcupuncture medication combinedOsteonecrosis of the femoral headBone metabolismBone marrow edemaInflammatory factors

《上海针灸杂志》 2026 (5)

542-547,6

河南省科技攻关项目(232102310423)河南省中医药科学研究专项课题(2024ZY2115)河南省中医药科学研究专项课题(2024ZY2108)河南省中医药科学研究专项课题(2022ZYZD14)河南省中医药科学研究专项课题(20-21ZY1026)2022年国家青年岐黄学者培养项目[国中医药人教函(2022)256号]

10.13460/j.issn.1005-0957.2025.14.0018

评论